Clinical Epidemiology and Ageing

Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review.

Fonteyne V, Ost P, Bellmunt J, Droz JPierre, Mongiat-Artus P, Inman B, Paillaud E, Saad F, Ploussard G Eur Urol. 2018;73(1):40-50.

<p><b>CONTEXT: </b>The incidence of muscle invasive bladder cancer (MIBC) increases with age. With increased life expectancy the number of elderly MIBC patients is expected to increase. Existing guidelines on management of MIBC do not preclude curative treatments for elderly patients. However, it is necessary to assess the risks and benefits of a treatment to avoid overtreatment that results in decreased health-related quality of life without prolonging survival.</p><p><b>OBJECTIVE: </b>To report on overall survival (OS), cancer specific survival (CSS), and morbidity after curative treatment in elderly patients, defined as age >70 yr, with nonmetastatic MIBC and to compare this with the outcome of younger MIBC patients.</p><p><b>EVIDENCE ACQUISITION: </b>A systematic review was performed using Medline, PubMed, and Embase databases. Articles were included if they addressed one of the three research questions: Only articles including >100 patients and with a clear age-stratification were included.</p><p><b>EVIDENCE SYNTHESIS: </b>Forty-two articles were retrieved for review. No article directly addressed the use of geriatric assessment. OS and CSS worsen significantly with age both after radical cystectomy and radiotherapy regimens. While POM significantly increases with age, morbidity seems comparable between younger and older patients.</p><p><b>CONCLUSIONS: </b>Although a proportion of elderly patients with MIBC will benefit from curative treatment, we observed worse OS, CSS, and POM with age. The impact of age on late morbidity is less clear. Prospective studies evaluating geriatric assessments are critically needed to optimize MIBC management in the elderly.</p><p><b>PATIENT SUMMARY: </b>We performed a systematic review to evaluate the outcome and complication rate in elderly patients with muscle invasive bladder cancer. We observed that overall survival and cancer specific survival significantly decrease and perioperative mortality significantly increases with age. The impact of age on late morbidity is less clear. There is a need for geriatric assessments to select those patients that will benefit from curative treatment.</p>

MeSH terms: Age Factors; Aged; Aged, 80 and over; Clinical Decision-Making; Cystectomy; Disease-Free Survival; Female; Geriatric Assessment; Humans; Life Expectancy; Male; Middle Aged; Neoplasm Invasiveness; Odds Ratio; Patient Selection; Quality of Life; Radiotherapy; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms
DOI: 10.1016/j.eururo.2017.03.019